

# Predictive value of mean platelet volume in young patients with non-ST-segment elevation acute coronary syndromes: a retrospective observational study

*ST-yükselmesi akut koroner sendromlu genç hastalarda ortalama trombosit hacminin öngördürücü değeri: Geriye dönük gözlemsel bir çalışma*

Mehmet Fatih Özlü, Serkan Öztürk, Suzi Selim Ayhan, Mehmet Tosun\*, Aytakin Alçelik\*\*, Alim Erdem, Mehmet Yazıcı

From Departments of Cardiology, \*Biochemistry and \*\*Internal Medicine, Faculty of Medicine, İzzet Baysal University, Bolu-Turkey

## ABSTRACT

**Objective:** Platelets play an important role in both initiation and propagation of acute coronary syndromes. We sought to evaluate the predictive value of mean platelet volume (MPV) in young patients with non-ST-segment elevation acute coronary syndromes (NSTEMI-ACS).

**Methods:** This is a retrospective observational study; evaluating the MPV values of 79 NSTEMI-ACS patients aged under 45 years and 45 control subjects having normal coronary anatomy. NSTEMI-ACS group was composed of 41 non-ST elevation myocardial infarction (NSTEMI) and 38 unstable angina pectoris (USAP) patients. MPV was measured using an automated hematology analyzer called Coulter counter. The predictive value of MPV was evaluated using logistic regression analysis and comparison of MPV between NSTEMI-ACS and control groups was performed by Mann-Whitney U test.

**Results:** The MPV was found to be significantly higher in the NSTEMI-ACS compared with control group ( $8.49 \pm 1.22$  versus  $7.78 \pm 0.65$  fL,  $p=0.001$ ). In logistic regression analysis, MPV was found to be an independent predictor of NSTEMI-ACS (OR=3.1, 95% CI 1.2-8.2,  $p=0.022$ ). The MPV values of NSTEMI group were not significantly different from USAP group ( $8.78 \pm 1.38$  versus  $8.17 \pm 0.95$  fL,  $p=0.66$ ). Similarly, the MPV values of the 3 groups (Control, USAP and NSTEMI) were found to be significantly different ( $7.78 \pm 0.65$ ,  $8.18 \pm 0.95$ ,  $8.78 \pm 1.38$  fL respectively,  $p=0.001$ ).

**Conclusion:** In conclusion, MPV was found to be elevated in NSTEMI-ACS patients compared with control subjects in young population. In addition, increased MPV was established to be an independent predictor of NSTEMI-ACS. (*Anadolu Kardiyol Derg 2013; 13: 57-61*)

**Key words:** Young patients, acute coronary syndrome, mean platelet volume, regression analysis

## ÖZET

**Amaç:** Trombositler akut koroner sendromların oluşumu ve ilerlemesinde önemli bir rol oynamaktadır. Bu çalışmada ST yükselmesi olmayan akut koroner sendromlu (NSTEMI-AKS) genç hastalarda ortalama trombosit hacminin öngördürücü değerini araştırmayı amaçladık.

**Yöntemler:** Bu, 45 yaş altındaki 79 NSTEMI-AKS hastasının ve normal koroner anatomiye sahip 45 kontrol bireyinin MPV değerlerini karşılaştıran geriye dönük gözlemsel bir çalışmadır. NSTEMI-AKS grubunu 41 ST yükselmesi olmayan miyokart enfarktüsü (NSTEMI) ve 38 kararsız angina pectoris (USAP) hastası oluşturmuştur. MPV, Coulter Sayaç adı verilen otomatik bir hematolojik tahlil cihazı kullanılarak ölçülmüştür. MPV'nin prediktif değeri lojistik regresyon analizi kullanılarak ve NSTEMI-AKS ve kontrol grupları arasında MPV karşılaştırılması Mann-Whitney U testi ile değerlendirilmiştir.

**Bulgular:** NSTEMI-AKS grubundaki MPV değerleri kontrol grubuna göre anlamlı olarak yüksek bulundu ( $8.49 \pm 1.22$ 'a karşılık  $7.78 \pm 0.65$  fL,  $p=0.001$ ). Lojistik regresyon analizinde, MPV'nin NSTEMI-AKS'nin bağımsız bir belirleyicisi olduğu bulunmuştur (OR=3.1, %95 CI 1.2-8.2,  $p=0.022$ ). NSTEMI grubunda MPV değerleri USAP grubundan anlamlı olarak farklı değildi ( $8.78 \pm 1.38$  versus  $8.17 \pm 0.95$  fL,  $p=0.66$ ). Benzer

**Address for Correspondence/Yazışma Adresi:** Dr. Mehmet Fatih Özlü, Abant İzzet Baysal Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, 14280, Bolu-Türkiye Phone: +90 374 253 46 56 Fax: +90 374 253 46 15 E-mail: drmf0@yahoo.com

**Accepted Date/Kabul Tarihi:** 29.08.2012 **Available Online Date/Çevrimiçi Yayın Tarihi:** 19.10.2012

© Telif Hakkı 2013 AVES Yayıncılık Ltd. Şti. - Makale metnine [www.anakarder.com](http://www.anakarder.com) web sayfasından ulaşılabilir.

© Copyright 2013 by AVES Yayıncılık Ltd. - Available on-line at [www.anakarder.com](http://www.anakarder.com)

doi:10.5152/akd.2013.007



şekilde, 3 grubun (Kontrol, USAP ve NSTEMI) MPV değerleri arasında anlamlı derecede farklılık olduğu tespit edilmiştir ( $7.78\pm 0.65$ ,  $8.18\pm 0.95$ ,  $8.78\pm 1.38$  fL respectively,  $p=0.001$ ).

**Sonuç:** Sonuç olarak, kontrol grubu ile karşılaştırıldığında genç NSTE-AKS hastalarında MPV değerleri daha yüksek bulunmuştur. Aynı zamanda artmış MPV, NSTE-AKS'in bağımsız bir belirleyicisi olarak bulunmuştur.  
(*Anadolu Kardiyol Derg 2013; 13: 57-61*)

**Anahtar kelimeler:** Genç hastalar, akut koroner sendromlar, ortalama trombosit hacmi, regresyon analizi

## Introduction

Platelets play a key role in both initiation and propagation of acute coronary syndromes (ACS) (1, 2). Mean platelet volume (MPV) is an important hematologic variable and indicator of platelet function (3, 4). Larger platelets are more active and have higher thrombotic potential (5, 6). They are also denser (7), have higher thromboxane A2 levels (8), and express more glycoprotein Ib and IIb/IIIa receptors (9), thus, larger platelets are aggregate more rapidly with collagen than smaller platelets (10). In a recent trial, high MPV was found to be an independent predictor of ST-segment elevation myocardial infarction (STEMI) in young patients (11).

Non-ST-segment elevation acute coronary syndrome (NSTE-ACS) differs from STEMI with a pathophysiological background involving mainly platelets rather than the Şbrin pathway (1). Thus, platelets play a central role in the pathogenesis of NSTE-ACS.

Young persons with ACS display a unique risk profile compared with older patients (12, 13). ACS are most frequently seen in older population; only a little part of acute coronary syndromes occurs among young population. Although its prevalence is increasing among young people, there are limited numbers of studies about the predictors of ACS in young patients (12, 13).

In this regard, we hypothesized that an increased mean platelet volume predicts development of NSTE-ACS and we evaluated the MPV of young patients with NSTE-ACS and control subjects in this study.

## Methods

### Study design

This is a retrospective observational study.

### Study population

Overall, 79 patients, younger than 45 years old, with the diagnosis of NSTE-ACS (41 NSTEMI, 38 USAP) were included in the study. The control group was comprised of 45 subjects, who were younger than 45 years old with normal coronary arteries. All the NSTE-ACS patients had been hospitalized within the first 24 hour of their chest pain between May 2009 and February 2011. Only patients with the first acute coronary event were assessed. Permission for the study was obtained from local ethics committee of Abant İzzet Baysal University.

## Data collection and definitions

Hospital medical records were retrospectively analyzed. Diagnosis of NSTEMI or USAP was made by assessing unstable chest pain, typical electrocardiographic changes and/or elevation of cardiac enzymes (1). Also medical history, drug use, body mass index (BMI) and the other risk factors like diabetes mellitus, hypertension, hyperlipidemia, and cigarette smoking were recorded. Hypertension was diagnosed according to the Joint National Committee (JNC) 7 report as blood pressure above 140/90 mmHg or having anti-hypertensive therapy (14). Diabetes mellitus was diagnosed as one of these criteria; Symptoms of diabetes plus any time plasma glucose concentration  $\geq 200$  mg/dL, FPG  $\geq 126$  mg/dL, 2-h post load glucose  $\geq 200$  mg/dL (11.1 mmol/l) during an OGTT or active use of anti-diabetic treatment (15) Family history of CAD was diagnosed if patients had a first degree male relative under 55 years of age or a female relative less than 65 years of age with CAD (1). Patients who were smoking before hospitalization were accepted as smokers. Coronary angiography was performed by the Judkin's technique.

## Laboratory analysis

Blood samples were obtained into blood collection tubes with ethylenediaminetetraacetic acid from all patients on admission in all cases. Hemoglobin, platelet count and MPV measurements were performed within approximately 60 minutes after blood sampling with Coulter LH 780 Analyzer and Coulter Hmx Hematology Analyzer (Beckman Coulter, Inc. CA, USA) with original method and reagents. LDL-C was calculated using the Friedewald formula. The other laboratory parameters were determined with standard methods.

## Statistical analysis

Statistical analyses were performed the SPSS software version 15.0 (SPSS Inc. IL, USA). Continuous variables were presented as mean  $\pm$  standard deviation. Nominal variables were presented as the percentage. As the MPV was not normally distributed, shown by Kolmogorov-Smirnov test, Mann-Whitney U test was conducted in the comparison of MPV of NSTE-ACS and control group. The MPV values of the 3 groups (Control, USAP and NSTEMI) were compared with Kruskal-Wallis tests. The univariate analyses to identify variables associated with patient outcome (NSTE-ACS) was investigated using Chi-square, Fisher exact, Student's t and Mann-Whitney U tests, where appropriate. For the multivariate analysis, the possible factors identified with univariate analyses were further entered into logistic regression analysis to determine the independent pre-

dictors of NSTEMI-ACS. Hosmer-Lemeshow goodness of fit statistics was used to assess model fit. A 5% type-I error level was used to infer statistical significance.

## Results

Demographic, medical and biochemical characteristics of controls and patients with NSTEMI-ACS are shown in Table 1. Hypertension, diabetes mellitus, smoking and family history were significantly higher in NSTEMI-ACS patients. In addition, high-density lipoprotein levels were significantly lower and triglycerides were significantly higher in NSTEMI-ACS patients. There was no difference in platelet counts between the groups ( $p=0.874$ ).

The MPV was found to be significantly higher in the NSTEMI-ACS compared with control group ( $8.49\pm 1.22$  versus  $7.78\pm 0.65$ ,  $p=0.001$ ) (Fig. 1). In addition, the MPV values of NSTEMI group were not significantly different from USAP group ( $8.78\pm 1.38$  versus  $8.17\pm 0.95$ ,  $p=0.66$ ). The mean of the MPV values were found to be significantly different among 3 groups (Control, USAP and NSTEMI) ( $7.78\pm 0.65$ ,  $8.18\pm 0.95$ ,  $8.78\pm 1.38$  respectively,  $p=0.001$ ) (Fig. 1).

According to the logistic regression analysis, male gender, smoking, body mass index and MPV were found to be independent predictors of NSTEMI-ACS (Table 2). The fit of the developed model was tested using Hosmer-Lemeshow test. The p value of this test was found to be 0.28, meaning that the model had a high prediction value. Also, it was estimated that one unit increase in the MPV leads to 3.1 fold increased risk of NSTEMI-ACS.

## Discussion

The main findings of the present study are; increased MPV was found to be an independent predictor of NSTEMI-ACS in young patients and MPV of the young patients with NSTEMI-ACS was found to be significantly higher than the MPV of the subjects of control group.


In acute coronary syndromes, a thrombogenic medium usually arises around the atherosclerotic plaque, and this can lead to adverse clinical outcomes. The thrombus formed on the disrupted endothelium can enlarge after plaque rupture or erosion. Platelet functions are very important, especially in the pathophysiology of arterial thrombosis. MPV is an important marker of platelet activity, which is measured as aggregation, vasoactive amine release, or the expression of specific receptors (16, 17).

The metabolic and enzymatic activity of the platelets increase as the platelet volume increases (18). The vasoactive mediators secreted by the platelets may contribute the inflammatory and atherogenesis process. So, increased risk of acute coronary syndromes in young patients with high MPV may be explained with the increased activity of platelets, increased inflammation and increased platelet aggregation (19).

**Table 1. Demographic, medical and biochemical characteristics of controls and patients with NSTEMI-ACS**

| Variables                        | NSTEMI-ACS (n=79) | Control (n=45) | *p      |
|----------------------------------|-------------------|----------------|---------|
| Age, years                       | 41.0±4.3          | 40.9±5.2       | 0.058   |
| Gender, M/F, n                   | 58/21             | 30/15          | <0.0001 |
| Smoking, n (%)                   | 54 (68.3)         | 4 (8.2)        | <0.0001 |
| Hypertension, n (%)              | 27 (34.1)         | 3 (6.7)        | <0.0001 |
| Diabetes mellitus, n (%)         | 9 (11.3)          | 1 (2.2)        | 0.035   |
| Family history, n (%)            | 38 (48.1)         | 5 (11.1)       | 0.001   |
| Hemoglobin, g/dL                 | 14.6±1.6          | 13.6±1.5       | 0.002   |
| MPV, fL                          | 8.49±1.22         | 7.78±0.65      | 0.001   |
| Platelet count, x10 <sup>3</sup> | 267±79            | 263±74         | 0.874   |
| TC, mg/dL                        | 182.8±36.2        | 173.1±34.1     | 0.136   |
| LDL, mg/dL                       | 107.5±32.3        | 102.8±27.2     | 0.319   |
| HDL, mg/dL                       | 32.8 ± 6.2        | 41.1±7.3       | <0.0001 |
| Triglyceride, mg/dL              | 213±98            | 126±58         | <0.0001 |

Data are presented as mean±SD, median (interquartile range) and number (percentage)  
\*Independent sample t-test, Mann-Whitney U test and Chi-square tests  
HDL- high- density lipoprotein, LDL-low-density lipoprotein, MPV- mean platelet volume, NSTEMI-ACS- non-ST elevation acute coronary syndromes, TC-total cholesterol



**Figure 1. Mean platelet volumes of patients with NSTEMI-ACS and control subjects (Mean values; Control: 7.78 fL, USAP: 8.18 fL, NSTEMI: 8.78 fL)**

\*Kruskal-Wallis test Chi-square=15,134, p for trend <0.001

**Table 2. Independent predictors of NSTEMI-ACS**

| Risk factors | RR (95% CI)*      | *p    |
|--------------|-------------------|-------|
| Sex(male)    | 89.2 (4.6-1747.8) | 0.003 |
| Smoking      | 18.2 (3.5-93.0)   | 0.001 |
| BMI          | 1.8 (1.2-2.7)     | 0.007 |
| MPV          | 3.1 (1.2- 8.2)    | 0.022 |

\* Logistic regression analysis  
BMI - body mass index, MPV - mean platelet volume, NSTEMI-ACS - non-ST elevation acute coronary syndromes, RR - the estimated relative risk shown by odds ratio and 95% confidence interval

Many studies of MPV in ACS have been published. In one of them, MPV was found to be elevated in patients with STEMI (20). In another, Pereg et al. (21) found an association between unsuccessful thrombolytic therapy and an increased MPV in patients with STEMI. Also, Chu et al. (22) reported an association between MPV and acute myocardial infarction in a recent meta-analysis. Further, they reported that MPV is related with MI mortality and restenosis. However, none of these studies evaluated patients with ACS who were younger than 45 years old. In our study, MPV was evaluated in young patients with NSTEMI-ACS. Thrombogenic activity is known to be higher in NSTEMI-ACS, and it has been shown to play an essential role in the etiopathogenesis of NSTEMI-ACS (1, 23). Likewise, MPV were found to be higher in myocardial infarction patients with normal coronary arteries (24). This supports that the acute coronary syndromes comprises on the basis of increased thrombogenic activity shown by high MPV, rather than atherosclerotic basis. In our study there was no acute coronary syndrome patient with normal coronary arteries.

In a study of premature atherosclerosis, Kurrelmeyer et al. (25) evaluated the role of sex differences in platelet function among subjects with a family history of premature coronary artery disease (CAD). They found that platelets from females were more reactive than platelets from males with a family history of premature CAD. In our study, the proportion of females was low in both the NSTEMI-ACS and control groups; moreover, the proportion of women was higher in the control group. Despite the possible increased platelet activity among females, MPV was found to be higher in the NSTEMI-ACS group in our study.

As expected, cardiovascular risk factors, including smoking, family history, hypertension, and diabetes mellitus, were more prevalent in young patients with NSTEMI-ACS than in the control group. Varol et al. (26) found that the serum MPV was significantly higher in regular smokers than in controls. Similarly, we found that the MPV in NSTEMI-ACS patients who smoked was higher than those in non-smoking NSTEMI-ACS patients. In another study, platelet activity was reported to decrease with advancing age (27). This indicates that platelet activity is higher in young patients, as compared to older patients. The high MPV we found in young patients with NSTEMI-ACS may be associated with the increased level of platelet activity in this population. Therefore, MPV may be more important in premature atherosclerosis, and NSTEMI-ACS patients with a high MPV may be more prone to acute coronary events.

### Study limitations

The major limitation of the study is the relatively low number of patients. In addition, MPV was evaluated only once; however, measurement of MPV after the acute phase could provide important data about the platelet functions and premature ACS.

### Conclusion

In conclusion, MPV was found to be elevated in young patients with NSTEMI-ACS compared with control subjects. Also,

increased MPV was found to be an independent predictor of NSTEMI-ACS. The platelet functions assessed by MPV may be more important in young patients with NSTEMI-ACS. Additional studies are needed to elucidate this relationship.

**Conflict of interest:** None declared.

**Peer-review:** Externally peer-reviewed.

**Authorships contributions:** Concept- M.F.Ö., S.Ö.; Design - S.Ö.; Supervision - S.S.A., M.Y.; Resource- A.E., M.T., M.Y.; Materials - A.A., M.T.; Data Collection&/or Processing - M.F.Ö., A.A., S.S.A., M.Y.; Analysis&/or Interpretation - M.T.; Literature Search - A.A., A.E.; Writing - F.Ö., A.E.; Critical Reviews - S.S.A., M.Y., A.Ö., A.E.

### Acknowledgements

Thanks to Ass. Prof. Yalçın Karagöz from the numerical methods department of Abant İzzet Baysal University for the statistical analysis support.

### References

- Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). *J Am Coll Cardiol* 2002;40:1366-74. [\[CrossRef\]](#)
- Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. *N Engl J Med* 1986;315:983-9. [\[CrossRef\]](#)
- Levin J, Bessman JD. The inverse relation between platelet volume and platelet number. Abnormalities in hematologic disease and evidence that platelet size does not correlate with platelet age. *J Lab Clin Med* 1983;101:295-307.
- Thompson CB, Jakubowski JA. The pathophysiology and clinical relevance of platelet heterogeneity. *Blood* 1988;72:1-8.
- Karpatkin S, Strick N. Heterogeneity of human platelets. V. Differences in glycolytic and related enzymes with possible relation to platelet age. *J Clin Invest* 1972;51:1235-43. [\[CrossRef\]](#)
- van der Loo B, Martin JF. A role for changes in platelet production in the cause of acute coronary syndromes. *Arterioscler Thromb Vasc Biol* 1999;19:672-9. [\[CrossRef\]](#)
- Karpatkin S. Heterogeneity of human platelets. I. Metabolic and kinetic evidence suggestive of young and old platelets. *J Clin Invest* 1969;48:1073-82. [\[CrossRef\]](#)
- Jakubowski JA, Thompson CB, Vaillancourt R, Valeri CR, Deykin D. Arachidonic acid metabolism by platelets of differing size. *Br J Haematol* 1983;53:503-11. [\[CrossRef\]](#)
- Giles H, Smith RE, Martin JF. Platelet glycoprotein IIb-IIIa and size are increased in acute myocardial infarction. *Eur J Clin Invest* 1994;24:69-72. [\[CrossRef\]](#)
- Martin JF, Trowbridge EA, Salmon G, Plumb J. The biological significance of platelet volume: its relationship to bleeding time, platelet thromboxane B2 production and megakaryocyte nuclear DNA concentration. *Thromb Res* 1983;32:443-60. [\[CrossRef\]](#)
- Özkan B, Uysal OK, Duran M, Şahin DY, Elbasan Z, Tekin K, et al. Relationship between mean platelet volume and atherosclerosis in

- young patients with ST elevation myocardial infarction. *Angiology* 2012 Jun 4. [Epub ahead of print]
12. Carro A, Bastiaenen R, Kaski JC. Age related issues in reperfusion of myocardial infarction. *Cardiovasc Drugs Ther* 2011;25:139-48. [\[CrossRef\]](#)
  13. Panduranga P, Sulaiman K, Al-Zakwani I, Abdelrahman S. Acute coronary syndrome in young adults from oman: results from the gulf registry of acute coronary events. *Heart Views* 2010;11:93-8. [\[CrossRef\]](#)
  14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003;289:2560-72. [\[CrossRef\]](#)
  15. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2006;29 Suppl 1:S43-8.
  16. Bath PM, Butterworth RJ. Platelet size: measurement, physiology and vascular disease. *Blood Coagul Fibrinolysis* 1996;7:157-61. [\[CrossRef\]](#)
  17. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: Is there a practical index of platelet activity? *Clin Appl Thromb Hemost* 2003;9:177-90. [\[CrossRef\]](#)
  18. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. *J Clin Invest* 2005;115:3378-84. [\[CrossRef\]](#)
  19. Neumann FJ, Marx N, Gawaz M, Brand K, Ott I, Rokitta C, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. *Circulation* 1997;95:2387-94 [\[CrossRef\]](#)
  20. Kishk YT, Trowbridge EA, Martin JF. Platelet volume subpopulations in acute myocardial infarction: an investigation of their homogeneity for smoking, infarct size and site. *Clin Sci (Lond)* 1985;68:419-25.
  21. Pereg D, Berlin T, Mosseri M. Mean platelet volume on admission correlates with impaired response to thrombolysis in patients with ST-elevation myocardial infarction. *Platelets* 2010;21:117-21. [\[CrossRef\]](#)
  22. Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. *J Thromb Haemost* 2010;8:148-56. [\[CrossRef\]](#)
  23. Yılmaz MB, Cihan G, Güray Y, Güray U, Kısacık HL, Şaşmaz H, et al. Role of mean platelet volume in triagging acute coronary syndromes. *J Thromb Thrombolysis* 2008;26:49-54. [\[CrossRef\]](#)
  24. Varol E, İçli A, Özaydın M, Erdoğan D, Arslan A. Mean platelet volume is elevated in patients with myocardial infarction with normal coronary arteries, as in patients with myocardial infarction with obstructive coronary artery disease. *Scand J Clin Lab Invest* 2009;69:570-4. [\[CrossRef\]](#)
  25. Kurrelmeyer K, Becker L, Becker D, Yanek L, Goldschmidt-Clermont P, Bray PF. Platelet hyperreactivity in women from families with premature atherosclerosis. *J Am Med Womens Assoc* 2003;58:272-7.
  26. Varol E, İçli A, Koçyiğit S, Erdoğan D, Özaydın M, Doğan A. Effect of smoking cessation on mean platelet volume. *Clin Appl Thromb Hemost* 2012 Feb 12. [Epub ahead of print] [\[CrossRef\]](#)
  27. Gilstad JR, Gurbel PA, Andersen RE. Relationship between age and platelet activation in patients with stable and unstable angina. *Arch Gerontol Geriat* 2009;48:155-9. [\[CrossRef\]](#)